Trial Profile
A Phase III, Multicenter, Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2019
Price :
$35
*
At a glance
- Drugs Alcaftadine/ketorolac (Primary) ; Alcaftadine
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Ajanta Pharma
- 26 Mar 2019 Status has been changed to completed.
- 13 Dec 2018 New trial record